The Adnectin CT-322 is a novel VEGF receptor 2 inhibitor that decreases tumor burden in an orthotopic mouse model of pancreatic cancer

BMC Cancer

Volumn 8, Issue , 2008, Pages

  Dineen, Sean P ^a   Sullivan, Laura A ^a   Beck, Adam W ^a   Miller, Andrew F ^a   Carbon, Juliet G ^a   Mamluk, Roni ^b   Wong, Henry ^b   Brekken, Rolf A ^a,b  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^b A Bristol Myers Squibb R and D Company   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CT 322; GEMCITABINE; UNCLASSIFIED DRUG; VASCULOTROPIN INHIBITOR; ANGIOGENESIS INHIBITOR; ANTINEOPLASTIC AGENT; DEOXYCYTIDINE; DRUG DERIVATIVE; VASCULOTROPIN RECEPTOR 2;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER INHIBITION; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; HUMAN CELL; IN VIVO STUDY; MONOTHERAPY; MOUSE; NONHUMAN; PANCREAS CANCER; TUMOR GROWTH; TUMOR VASCULARIZATION; ANIMAL; C57BL MOUSE; DISEASE MODEL; DRUG ANTAGONISM; DRUG SCREENING; METASTASIS; NECROSIS; NEOVASCULARIZATION (PATHOLOGY); NUDE MOUSE; PANCREAS TUMOR; PATHOLOGY; TREATMENT OUTCOME; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CELL LINE, TUMOR; DEOXYCYTIDINE; DISEASE MODELS, ANIMAL; FEMALE; HUMANS; MICE; MICE, INBRED C57BL; MICE, NUDE; NECROSIS; NEOPLASM METASTASIS; NEOVASCULARIZATION, PATHOLOGIC; PANCREATIC NEOPLASMS; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR RECEPTOR-2; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 60549096767     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-8-352     Document Type: Article

References (24)

1. Jemal A Siegel R Ward E Hao Y Xu J Murray T Thun MJ Cancer statistics, 2008 CA Cancer J Clin 2008, 58(2):71-96. 10.3322/CA.2007.0010 18287387
2. Hanahan D Weinberg RA The hallmarks of cancer Cell 2000, 100(1):57-70. 10.1016/S0092-8674(00)81683-9 10647931
3. Folkman J Angiogenesis in cancer, vascular, rheumatoid and other disease Nature medicine 1995, 1(1):27-31. 10.1038/nm0195-27 7584949
4. Takahashi H Shibuya M The vascular endothelial growth factor (VEGF)/VEGF receptor system and its role under physiological and pathological conditions Clin Sci (Lond) 2005, 109(3):227-241. 16104843
5. Kerbel RS Tumor angiogenesis The New England journal of medicine 2008, 358(19):2039-2049. 10.1056/NEJMra0706596 18463380
6. Yamazaki Y Morita T Molecular and functional diversity of vascular endothelial growth factors Molecular diversity 2006, 10(4):515-527. 10.1007/s11030-006-9027-3 16972015
7. Sawano A Iwai S Sakurai Y Ito M Shitara K Nakahata T Shibuya M Flt-1, vascular endothelial growth factor receptor 1, is a novel cell surface marker for the lineage of monocyte-macrophages in humans Blood 2001, 97(3):785-791. 10.1182/blood.V97.3.785 11157498
8. Jain RK Duda DG Clark JW Loeffler JS Lessons from phase III clinical trials on anti-VEGF therapy for cancer Nature clinical practice 2006, 3(1):24-40. 10.1038/ncponc0403 16407877
9. Ferrara N Hillan KJ Gerber HP Novotny W Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 2004, 3(5):391-400. 10.1038/nrd1381 15136787
10. Hurwitz H Fehrenbacher L Novotny W Cartwright T Hainsworth J Heim W Berlin J Baron A Griffing S Holmgren E et al Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer The New England journal of medicine 2004, 350(23):2335-2342. 10.1056/NEJMoa032691 15175435
11. Sandler A Gray R Perry MC Brahmer J Schiller JH Dowlati A Lilenbaum R Johnson DH Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer The New England journal of medicine 2006, 355(24):2542-2550. 10.1056/NEJMoa061884 17167137
12. Gill DS Damle NK Biopharmaceutical drug discovery using novel protein scaffolds Curr Opin Biotechnol 2006, 17(6):653-658. 10.1016/ j.copbio.2006.10.003 17055245
13. Getmanova EV Chen Y Bloom L Gokemeijer J Shamah S Warikoo V Wang J Ling V Sun L Antagonists to human and mouse vascular endothelial growth factor receptor 2 generated by directed protein evolution in vitro Chemistry & biology 2006, 13(5):549-556. 10.1016/ j.chembiol.2005.12.009 16720276
14. Parker MH Chen Y Danehy F Dufu K Ekstrom J Getmanova E Gokemeijer J Xu L Lipovsek D Antibody mimics based on human fibronectin type three domain engineered for thermostability and high-affinity binding to vascular endothelial growth factor receptor two Protein Eng Des Sel 2005, 18(9):435-444. 10.1093/protein/gzi050 16087651
15. Beck AW Luster TA Miller AF Holloway SE Conner CR Barnett CC Thorpe PE Fleming JB Brekken RA Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice Int J Cancer 2006, 118(10):2639-2643. 10.1002/ijc.21684 16353142
16. Hallmann R Mayer DN Berg EL Broermann R Butcher EC Novel mouse endothelial cell surface marker is suppressed during differentiation of the blood brain barrier Dev Dyn 1995, 202(4):325-332. 7626790
17. Brekken RA Huang X King SW Thorpe PE Vascular endothelial growth factor as a marker of tumor endothelium Cancer Res 1998, 58(9):1952-1959. 9581838
18. Roskoski R Jr Vascular endothelial growth factor (VEGF) signaling in tumor progression Crit Rev Oncol Hematol 2007, 62(3):179-213. 10.1016/ j.critrevonc.2007.01.006 17324579
19. Koukourakis MI Giatromanolaki A Thorpe PE Brekken RA Sivridis E Kakolyris S Georgoulias V Gatter KC Harris AL Vascular endothelial growth factor/KDR activated microvessel density versus CD31 standard microvessel density in non-small cell lung cancer Cancer Res 2000, 60:3088-3095. 10850461
20. Folkman J Angiogenesis: An organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6(4):273-286. 10.1038/nrd2115 17396134
21. Miller K Wang M Gralow J Dickler M Cobleigh M Perez EA Shenkier T Cella D Davidson NE Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer The New England journal of medicine 2007, 357(26):2666-2676. 10.1056/NEJMoa072113 18160686
22. Kindler HL Friberg G Singh DA Locker G Nattam S Kozloff M Taber DA Karrison T Dachman A Stadler WM et al. Phase II trial of bevacizumab plus gemcitabine in patients with advanced pancreatic cancer J Clin Oncol 2005, 23(31):8033-8040. 10.1200/JCO.2005.01.9661 16258101
23. Kindler DNHL Hollis D Oraefo E Schrag D Hurwitz H McLeod HL Mulcahy MF Schilsky RL Goldberg RM Cancer and Leukemia Group B A double blind, placebo-controlled, randomized phase III trial of gemcitabine (G) plus bevacizumab (B) versus gemcitabine plus placebo (P) in patients (pts) with advanced pancreatic cancer (PC): A preliminary analysis of Cancer and Leukemia Group B Journal of Clinical Oncology 2007, 25(18S):4508. 17906219
24. Molckovsky A Siu LL First-in-class, first-in-human phase I results of targeted agents: Highlights of the 2008 American Society of Clinical Oncology meeting J Hematol Oncol 2008, 1(1):20. 10.1186/1756-8722-1-20 18959794